Cite
Ribi K, Luo W, Colleoni M, et al. Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. Br J Cancer. 2020;122(7):1119doi: 10.1038/s41416-019-0709-x.
Ribi, K., Luo, W., Colleoni, M., Karlsson, P., Chirgwin, J., Aebi, S., Jerusalem, G., Neven, P., Di Lauro, V., Gomez, H. L., Ruhstaller, T., Abdi, E., Biganzoli, L., Müller, B., Barbeaux, A., Graas, M. P., Rabaglio, M., Francis, P. A., Foukakis, T., Pagani, O., Graiff, C., Vorobiof, D., Maibach, R., Di Leo, A., Gelber, R. D., Goldhirsch, A., Coates, A. S., Regan, M. M., Bernhard, J. (2020). Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. British journal of cancer, 122(7), 1119. https://doi.org/10.1038/s41416-019-0709-x
Ribi, Karin, et al. "Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial." British journal of cancer vol. 122,7 (2020): 1119. doi: https://doi.org/10.1038/s41416-019-0709-x
Ribi K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Müller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J. Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. Br J Cancer. 2020 Mar;122(7):1119. doi: 10.1038/s41416-019-0709-x. PMID: 31949268; PMCID: PMC7109133.
Copy
Download .nbib